IRB #

IRB00007052

Title

A single-arm, open-label, multi-center study of complete molecular response (CMR) in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)

Principal Investigator

Michael Mauro

Study Purpose

The study would like to see if the approved drug Tasigna (nilotinib) can decrease an abnormal protein (Bcr-Abl) in the blood of subjects diagnosed with Chronic Myelogenous Leukemia (CML)

Medical Condition(s)

Chronic Myelogenous Leukemia

Eligibility Criteria

Males and Females, 18 years and older, with CML who are Philadelphia chromosome positive (Ph+)

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

At least 2 years

Minors Included

No

Contact

Traci Peterson 503.494.8945

Sponsor

Novartis

Recruitment End

07/31/2013

Compensation Provided

No